Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Change in Receivables (2018 - 2025)

10x Genomics' Change in Receivables history spans 8 years, with the latest figure at $3.2 million for Q4 2025.

  • For Q4 2025, Change in Receivables changed N/A year-over-year to $3.2 million; the TTM value through Dec 2025 reached -$41.3 million, changed N/A, while the annual FY2025 figure was -$41.3 million, N/A changed from the prior year.
  • Change in Receivables for Q4 2025 was $3.2 million at 10x Genomics, up from -$6.6 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $23.6 million in Q2 2024 and bottomed at -$35.3 million in Q1 2025.
  • The 5-year median for Change in Receivables is $3.2 million (2025), against an average of $1.2 million.
  • The largest annual shift saw Change in Receivables surged 3383.84% in 2023 before it tumbled 6399.02% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $6.8 million in 2021, then skyrocketed by 202.14% to $20.6 million in 2022, then plummeted by 46.78% to $11.0 million in 2023, then plummeted by 100.93% to -$102000.0 in 2024, then surged by 3268.63% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Change in Receivables are $3.2 million (Q4 2025), -$6.6 million (Q3 2025), and -$2.6 million (Q2 2025).